Key Metrics of InMode Ltd.
Revenue$492M▲ 8.3% YoYFY 2023
Operating income$196M▼ 1.1% YoY
Net profit$198M▲ 22.5% YoY
Shareholders' equity$787M
Market cap$789MINMD · $13.72
Competitors10identified
About InMode Ltd.
Sectors
Company details
- Founded
- 2019
- Listed
- Nasdaq: INMD (since 2019)
Operational Areas of InMode Ltd.
Pharmaceuticals & Healthcare›Biotechnology & Vaccines
Company summary
Legal nameInMode Ltd.
TickerINMD
ExchangeNasdaq
CountryIsrael
SEC CIK0001742692
Listed since2019
IndustryBiotechnology: Electromedical & Electrotherapeutic Apparatus
SectorPharmaceuticals & Healthcare · Biotechnology & Vaccines
Website—
US market & SEC filings
INMD · Nasdaq · SEC CIK 0001742692
Last price · 28 Oct 2026
$13.72
−1.79%
Market cap$789M
P/E6.0On FY 2023 diluted EPS
Volume671,583
SectorHealth CareBiotechnology: Electromedical & Electrotherapeutic Apparatus
Country · IPOIsraelListed 2019
INMD share price
Premium
Annual results (SEC EDGAR)
Revenue, operating income, net income, EPS, cash flow, assets, liabilities, equity and debt for every year filed with the SEC are part of the premium plan.
Sign in to continue See plans & pricingVendor checks & payment capacity
Sign in with access to company financials to review vendor evidence.
Registered office and contact
Registered office—
GSTIN—
Email—
Website—
Members / shareholders—
Directors and key people
Directors are read from the MGT-7 annual return and AOC-4 signatories.
Competitors of InMode Ltd.
Competitors10identified
Countries2most in United States
Top competitors by location
| Company | Description | Domain | Founded | Location |
|---|---|---|---|---|
| Part of Vertex Pharmaceuticals. | vrtx.com | 1991 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | gsk.com | 2022 | United Kingdom | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | modernatx.com | 2018 | United States | |
 Becton Dickinson |
Biotechnology & Vaccines · Pharmaceuticals & Healthcare | bd.com | — | United States |
| Part of Illumina. | illumina.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | guardanthealth.com | 2018 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | revvity.com | — | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | exelixis.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | neurocrine.com | 1996 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | biomarin.com | 1999 | United States |
Charges (secured borrowings)
0 registered charges. Lenders, amounts and dates are part of the premium plan.
Statutory auditors
Auditors are read from the AOC-4 auditor's report section.
Business activities and related parties
Principal business activities and related-party transactions are read from MGT-7 and AOC-4 filings.
Filings
No filings on record yet.